Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
Other equities analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. Wedbush restated an “outperform” rating and set a $38.00 target price on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Finally, ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $28.50.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at $9.24 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66. The stock has a market cap of $980.91, a PE ratio of -7.33 and a beta of 0.24. Lexicon Pharmaceuticals has a one year low of $8.07 and a one year high of $18.00.
In other Lexicon Pharmaceuticals news, CEO Lonnel Coats purchased 10,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $9.91 per share, with a total value of $99,100.00. Following the transaction, the chief executive officer now directly owns 42,985 shares of the company’s stock, valued at $425,981.35. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Public Equities L.P. Invus purchased 180,727 shares of Lexicon Pharmaceuticals stock in a transaction dated Friday, November 17th. The shares were acquired at an average cost of $10.11 per share, with a total value of $1,827,149.97. The disclosure for this purchase can be found here. 5.77% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantitative Systematic Strategies LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth approximately $117,000. Aperio Group LLC purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth approximately $127,000. Cubist Systematic Strategies LLC purchased a new stake in Lexicon Pharmaceuticals in the 3rd quarter worth approximately $149,000. Teacher Retirement System of Texas purchased a new stake in Lexicon Pharmaceuticals in the 4th quarter worth approximately $161,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $182,000.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/lexicon-pharmaceuticals-lxrx-upgraded-by-zacks-investment-research-to-hold.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.